The Experts below are selected from a list of 216 Experts worldwide ranked by ideXlab platform

Thomas H Tarter - One of the best experts on this subject based on the ideXlab platform.

  • serum heterophile antibodies interfere with prostate specific antigen test and result in over treatment in a patient with prostate cancer
    The Journal of Urology, 2001
    Co-Authors: Bradley R Morgan, Thomas H Tarter
    Abstract:

    Purpose: We evaluated how naturally occurring heterophile antibodies in patient serum interfered with prostate specific antigen (PSA) immunoassay, resulting in over treatment for prostate cancer.Materials and Methods: Serum samples were treated with heterophilic blocking reagent (Scantibodies Laboratory, Inc., Santee, California). Treated and untreated samples were tested by the Medics (Tosoh, Foster City, California) Tandem-R (Beckman-Coulter Inc., Chaska, Minnesota) and Elecsys (Roche Molecular Biochemical, Indianapolis, Indiana) PSA assays. Heterophile antibodies were measured directly in treated and untreated samples by the Human Anti-Mouse Antibody immunoradiometric assay and heterophilic Antibody identification enzyme immunoassay (Scantibodies Laboratories, Inc.).Results: Human Anti-Mouse Ig heterophile antibodies in patient serum caused false-positive PSA test findings after radical prostatectomy, resulting in over treatment for presumed disease recurrence.Conclusions: If PSA is detectable after ra...

  • SERUM HETEROPHILE ANTIBODIES INTERFERE WITH PROSTATE SPECIFIC ANTIGEN TEST AND RESULT IN OVER TREATMENT IN A PATIENT WITH PROSTATE CANCER
    The Journal of urology, 2001
    Co-Authors: Bradley R Morgan, Thomas H Tarter
    Abstract:

    We evaluated how naturally occurring heterophile antibodies in patient serum interfered with prostate specific antigen (PSA) immunoassay, resulting in over treatment for prostate cancer. Serum samples were treated with heterophilic blocking reagent (Scantibodies Laboratory, Inc., Santee, California). Treated and untreated samples were tested by the Medics (Tosoh, Foster City, California ) Tandem-R (Beckman-Coulter Inc., Chaska, Minnesota) and Elecsys (Roche Molecular Biochemical, Indianapolis, Indiana) PSA assays. Heterophile antibodies were measured directly in treated and untreated samples by the Human Anti-Mouse Antibody immunoradiometric assay and heterophilic Antibody identification enzyme immunoassay (Scantibodies Laboratories, Inc.). Human Anti-Mouse Ig heterophile antibodies in patient serum caused false-positive PSA test findings after radical prostatectomy, resulting in over treatment for presumed disease recurrence. If PSA is detectable after radical prostatectomy and the likelihood of incomplete resection or systemic disease is low, the presence of heterophile antibodies should be considered.

Chikara Shimizu - One of the best experts on this subject based on the ideXlab platform.

  • Transient Human Anti-Mouse Antibody generated with immune enhancement in a carbohydrate antigen 19-9 immunoassay after surgical resection of recurrent cancer.
    Annals of clinical biochemistry, 2016
    Co-Authors: Keiichi Nakano, Keiko Yasuda, Hitoshi Shibuya, Takanori Moriyama, Kaoru Kahata, Chikara Shimizu
    Abstract:

    We report a case of transient Human Anti-Mouse Antibody from a 64-year-old man in a carbohydrate antigen 19-9 immunoassay using an AIA 1800 analyser that generated immune enhancement after surgical resection of recurrent cancer. The carbohydrate antigen 19-9 concentration was measured using an AIA 1800 analyser and a UniCel Dxl 800. Size-exclusion high-performance liquid chromatography was carried out on a Superose 12 column to estimate the carbohydrate antigen 19-9 elution profile using an AIA 1800 analyser. To determine whether IgM in the patient contributed to the carbohydrate antigen 19-9 immunoassay, immunoprecipitation was performed. Furthermore, mouse immunoglobulins were added to the patient's serum to verify that the patient's IgM reacted with it. The carbohydrate antigen 19-9 concentration was >400 and 9.5 kU/L using an AIA 1800 analyser and using a UniCel Dxl 800, respectively. In the single carbohydrate antigen 19-9 peak, the molecular weight corresponded to IgM by size-exclusion high-performance liquid chromatography on a Superose 12 column. In the immunoprecipitation reaction and addition of mouse immunoglobulins, there was interference for anti-Human IgM and mouse immunoglobulins whose recoveries were 3.2 and 14.2%, respectively. These results indicated that IgM in the patient's serum interfered with the carbohydrate antigen 19-9 immunoassay using an AIA 1800 analyser. A novel transient Human Anti-Mouse Antibody generated with immune activation in a carbohydrate antigen 19-9 immunoassay using an AIA 1800 analyser was identified in a patient with rectal cancer after surgical resection. These findings demonstrate the importance of monitoring tumour markers in patients after treatment with mouse monoclonal Antibody. © The Author(s) 2016.

  • Transient Human Anti-Mouse Antibody generated with immune enhancement in a carbohydrate antigen 19-9 immunoassay after surgical resection of recurrent cancer
    Annals of Clinical Biochemistry, 2016
    Co-Authors: Keiichi Nakano, Keiko Yasuda, Hitoshi Shibuya, Takanori Moriyama, Kaoru Kahata, Chikara Shimizu
    Abstract:

    We report a case of transient Human Anti-Mouse Antibody from a 64-year-old man in a carbohydrate antigen 19-9 immunoassay using an AIA 1800 analyser that generated immune enhancement after surgical resection of recurrent cancer.MethodsThe carbohydrate antigen 19-9 concentration was measured using an AIA 1800 analyser and a UniCel Dxl 800. Size-exclusion high-performance liquid chromatography was carried out on a Superose 12 column to estimate the carbohydrate antigen 19-9 elution profile using an AIA 1800 analyser. To determine whether IgM in the patient contributed to the carbohydrate antigen 19-9 immunoassay, immunoprecipitation was performed. Furthermore, mouse immunoglobulins were added to the patient’s serum to verify that the patient’s IgM reacted with it.ResultsThe carbohydrate antigen 19-9 concentration was >400 and 9.5 kU/L using an AIA 1800 analyser and using a UniCel Dxl 800, respectively. In the single carbohydrate antigen 19-9 peak, the molecular weight corresponded to IgM by size-exclusion h...

Bradley R Morgan - One of the best experts on this subject based on the ideXlab platform.

  • serum heterophile antibodies interfere with prostate specific antigen test and result in over treatment in a patient with prostate cancer
    The Journal of Urology, 2001
    Co-Authors: Bradley R Morgan, Thomas H Tarter
    Abstract:

    Purpose: We evaluated how naturally occurring heterophile antibodies in patient serum interfered with prostate specific antigen (PSA) immunoassay, resulting in over treatment for prostate cancer.Materials and Methods: Serum samples were treated with heterophilic blocking reagent (Scantibodies Laboratory, Inc., Santee, California). Treated and untreated samples were tested by the Medics (Tosoh, Foster City, California) Tandem-R (Beckman-Coulter Inc., Chaska, Minnesota) and Elecsys (Roche Molecular Biochemical, Indianapolis, Indiana) PSA assays. Heterophile antibodies were measured directly in treated and untreated samples by the Human Anti-Mouse Antibody immunoradiometric assay and heterophilic Antibody identification enzyme immunoassay (Scantibodies Laboratories, Inc.).Results: Human Anti-Mouse Ig heterophile antibodies in patient serum caused false-positive PSA test findings after radical prostatectomy, resulting in over treatment for presumed disease recurrence.Conclusions: If PSA is detectable after ra...

  • SERUM HETEROPHILE ANTIBODIES INTERFERE WITH PROSTATE SPECIFIC ANTIGEN TEST AND RESULT IN OVER TREATMENT IN A PATIENT WITH PROSTATE CANCER
    The Journal of urology, 2001
    Co-Authors: Bradley R Morgan, Thomas H Tarter
    Abstract:

    We evaluated how naturally occurring heterophile antibodies in patient serum interfered with prostate specific antigen (PSA) immunoassay, resulting in over treatment for prostate cancer. Serum samples were treated with heterophilic blocking reagent (Scantibodies Laboratory, Inc., Santee, California). Treated and untreated samples were tested by the Medics (Tosoh, Foster City, California ) Tandem-R (Beckman-Coulter Inc., Chaska, Minnesota) and Elecsys (Roche Molecular Biochemical, Indianapolis, Indiana) PSA assays. Heterophile antibodies were measured directly in treated and untreated samples by the Human Anti-Mouse Antibody immunoradiometric assay and heterophilic Antibody identification enzyme immunoassay (Scantibodies Laboratories, Inc.). Human Anti-Mouse Ig heterophile antibodies in patient serum caused false-positive PSA test findings after radical prostatectomy, resulting in over treatment for presumed disease recurrence. If PSA is detectable after radical prostatectomy and the likelihood of incomplete resection or systemic disease is low, the presence of heterophile antibodies should be considered.

Joseph Gulfo - One of the best experts on this subject based on the ideXlab platform.

  • Radioimmunoscintigraphy with 111Indium Labeled Cyt-356 for the Detection of Occult Prostate Cancer Recurrence
    The Journal of Urology, 1994
    Co-Authors: Daniel Kahn, Richard Williams, David W. Seldin, John A. Libertino, Mark Hirschhorn, Robert Dreicer, George J. Weiner, David L. Bushnell, Joseph Gulfo
    Abstract:

    AbstractWe assessed the safety and ability of the 111indium labeled immunoconjugate 7E11-C5.3-glycyl-tyrosyl-(N, e-diethylenetriaminepentaacetic acid)-lysine (CYT-356) to detect sites of occult prostate cancer in 27 subjects who had undergone radical prostatectomy and whose only evidence of recurrent disease was an increasing (0.8 ng./ml. or greater) serum prostate specific antigen (PSA). All subjects underwent whole body scintigraphy between 2 and 4 days following the radiopharmaceutical injection. Routine blood work and Human Anti-Mouse Antibody titers were monitored. Scintigraphic findings were compared with clinical parameters, prostatic fossa biopsy results and conventional imaging techniques. Except for transient hypotension in 1 subject following the second infusion, no side effects or Human Anti-Mouse Antibody titers were detected. In 22 subjects 1 or more lesions were detected, of which 11 (50%) were confirmed by biopsy, computerized tomography or magnetic resonance imaging. Of 14 subjects with l...

  • Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence.
    The Journal of urology, 1994
    Co-Authors: Daniel Kahn, David W. Seldin, John A. Libertino, Mark Hirschhorn, Robert Dreicer, George J. Weiner, R D Williams, D Bushnell, Joseph Gulfo
    Abstract:

    We assessed the safety and ability of the 111indium labeled immunoconjugate 7E11-C5.3-glycyl-tyrosyl-(N,e-diethylenetriaminepentaacetic acid)-lysine (CYT-356) to detect sites of occult prostate cancer in 27 subjects who had undergone radical prostatectomy and whose only evidence of recurrent disease was an increasing (0.8 ng./ml. or greater) serum prostate specific antigen (PSA). All subjects underwent whole body scintigraphy between 2 and 4 days following the radiopharmaceutical injection. Routine blood work and Human Anti-Mouse Antibody titers were monitored. Scintigraphic findings were compared with clinical parameters, prostatic fossa biopsy results and conventional imaging techniques. Except for transient hypotension in 1 subject following the second infusion, no side effects or Human Anti-Mouse Antibody titers were detected. In 22 subjects 1 or more lesions were detected, of which 11 (50%) were confirmed by biopsy, computerized tomography or magnetic resonance imaging. Of 14 subjects with lesions in the prostatic fossa 13 had biopsies performed, 8 (62%) of which were positive. Magnetic resonance imaging confirmed tumor in the spine and chest computerized tomography findings were compatible with lesions seen in the mediastinum in 1 subject each. There was a statistically significant relationship between detecting a scan abnormality and the initial pathological stage of disease but not with the serum PSA. These data provide preliminary evidence that 111indium labeled CYT-356 can be safely administered and readministered, and it detects sites of occult prostate cancer recurrence in subjects whose PSA is increasing following radical prostatectomy.

Keiichi Nakano - One of the best experts on this subject based on the ideXlab platform.

  • Transient Human Anti-Mouse Antibody generated with immune enhancement in a carbohydrate antigen 19-9 immunoassay after surgical resection of recurrent cancer.
    Annals of clinical biochemistry, 2016
    Co-Authors: Keiichi Nakano, Keiko Yasuda, Hitoshi Shibuya, Takanori Moriyama, Kaoru Kahata, Chikara Shimizu
    Abstract:

    We report a case of transient Human Anti-Mouse Antibody from a 64-year-old man in a carbohydrate antigen 19-9 immunoassay using an AIA 1800 analyser that generated immune enhancement after surgical resection of recurrent cancer. The carbohydrate antigen 19-9 concentration was measured using an AIA 1800 analyser and a UniCel Dxl 800. Size-exclusion high-performance liquid chromatography was carried out on a Superose 12 column to estimate the carbohydrate antigen 19-9 elution profile using an AIA 1800 analyser. To determine whether IgM in the patient contributed to the carbohydrate antigen 19-9 immunoassay, immunoprecipitation was performed. Furthermore, mouse immunoglobulins were added to the patient's serum to verify that the patient's IgM reacted with it. The carbohydrate antigen 19-9 concentration was >400 and 9.5 kU/L using an AIA 1800 analyser and using a UniCel Dxl 800, respectively. In the single carbohydrate antigen 19-9 peak, the molecular weight corresponded to IgM by size-exclusion high-performance liquid chromatography on a Superose 12 column. In the immunoprecipitation reaction and addition of mouse immunoglobulins, there was interference for anti-Human IgM and mouse immunoglobulins whose recoveries were 3.2 and 14.2%, respectively. These results indicated that IgM in the patient's serum interfered with the carbohydrate antigen 19-9 immunoassay using an AIA 1800 analyser. A novel transient Human Anti-Mouse Antibody generated with immune activation in a carbohydrate antigen 19-9 immunoassay using an AIA 1800 analyser was identified in a patient with rectal cancer after surgical resection. These findings demonstrate the importance of monitoring tumour markers in patients after treatment with mouse monoclonal Antibody. © The Author(s) 2016.

  • Transient Human Anti-Mouse Antibody generated with immune enhancement in a carbohydrate antigen 19-9 immunoassay after surgical resection of recurrent cancer
    Annals of Clinical Biochemistry, 2016
    Co-Authors: Keiichi Nakano, Keiko Yasuda, Hitoshi Shibuya, Takanori Moriyama, Kaoru Kahata, Chikara Shimizu
    Abstract:

    We report a case of transient Human Anti-Mouse Antibody from a 64-year-old man in a carbohydrate antigen 19-9 immunoassay using an AIA 1800 analyser that generated immune enhancement after surgical resection of recurrent cancer.MethodsThe carbohydrate antigen 19-9 concentration was measured using an AIA 1800 analyser and a UniCel Dxl 800. Size-exclusion high-performance liquid chromatography was carried out on a Superose 12 column to estimate the carbohydrate antigen 19-9 elution profile using an AIA 1800 analyser. To determine whether IgM in the patient contributed to the carbohydrate antigen 19-9 immunoassay, immunoprecipitation was performed. Furthermore, mouse immunoglobulins were added to the patient’s serum to verify that the patient’s IgM reacted with it.ResultsThe carbohydrate antigen 19-9 concentration was >400 and 9.5 kU/L using an AIA 1800 analyser and using a UniCel Dxl 800, respectively. In the single carbohydrate antigen 19-9 peak, the molecular weight corresponded to IgM by size-exclusion h...